Coronary Artery Calcification (CAC) Scoring with CT
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs the use of computed tomography to detect coronary artery calcification (CAC) for evaluation and risk stratification of coronary artery disease in BCBSKS members.
No material clinical or coverage changes in this revision.
Coverage Criteria
General Coverage
Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage for an individual member.
Contexts supported by evidence
Contexts where CAC scoring may be clinically useful based on available evidence:
Observational cohorts demonstrate reclassification and improved discrimination in intermediate-risk groups.
Cohort analyses (eg, Cainzos-Achirica, Budoff) support use of CAC to inform selection for preventive pharmacotherapy.
Systematic reviews and RCTs report improved risk factors and medication initiation but no consistent effect on hard outcomes.
Diagnostic use in symptomatic individuals
Covered when ALL of the following are met for symptomatic evaluation
Population of interest defined by symptomatic presentation.
Reflects trial protocols where CAC guided selective CCTA (eg, Lubbers et al).
Required documentation should record intended downstream actions based on CAC score.
Evidence-based stance
Evidence summary and implications
Further research, including RCTs demonstrating impact on clinical outcomes, is needed to establish clinical utility.
The policy designates the use of computed tomography (CT) to detect coronary artery calcification (CAC) as experimental/investigational. Coverage for CAC scoring is therefore excluded under this policy language, and final coverage determination for an individual member depends on the member's contract benefits in effect at the time of service.
Systematic reviews and meta-analyses of CAC screening in asymptomatic adults report improvements in some intermediate measures—such as initiation or adherence to preventive medications, modest improvements in lipids, and some self-reported lifestyle changes—but no included studies reported reductions in cardiovascular events or all-cause mortality after screening.
The evidence threshold for establishing clinical utility requires demonstration of clinical validity in studies that meet methodological criteria (including a suitable reference standard and adequate sample size). The policy notes that eligible diagnostic validity studies should report on the marketed technology, describe patient selection and characteristics, include a reference standard, and generally meet a minimum sample size (eg, ≥ 1,000 in selection criteria). If these clinical validity criteria are not met, inferences about clinical utility cannot be made and the use may not be supported.
Because systematic reviews and meta-analyses report inconsistent diagnostic accuracy—especially regarding whether a CAC score of 0 reliably excludes significant atherosclerotic CAD in symptomatic patients—and randomized controlled trial evidence on clinical outcomes is lacking, further research is needed. Clinicians should be cautious: a CAC score of 0 may lower the probability of an atherosclerotic cause but should not be assumed to definitively rule out disease without corroborating clinical assessment or follow-up testing where indicated.
Historically, the Coding section of this policy included a Diagnosis subsection stating: "Experimental/Investigational for all diagnoses related to this policy." This wording was added in prior revisions to align coding guidance with the policy's experimental/investigational stance.
Routine CAC screening of asymptomatic adults without a clinical indication or outside contexts where results would directly inform management decisions is not supported by evidence of improved clinical endpoints. Systematic reviews and pooled trial data do not demonstrate reductions in cardiovascular events or mortality for routine population screening.
Randomized trials that evaluated EBCT/CAC disclosure as a motivational intervention or to drive short‑term changes in calculated risk (eg, Framingham Risk Score) generally did not demonstrate meaningful benefit at 1 year. For example, an RCT assessing EBCT as a motivational tool in an asymptomatic population found no significant change in 10‑year Framingham Risk Score at 1 year. Thus, use of EBCT/CAC solely as a motivational tool or to change short‑term risk profiles is not supported by the cited RCT evidence.
Coding and Code Definitions
| JAK | FDA product code for CT devices used to detect coronary artery calcification |
| No codes listed |
| 75571 | Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium. |
| 75572 | Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed). |
| 75573 | Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function, and evaluation of vascular structures, if performed). |
| 75574 | Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing. |
| 0710T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report. |
| 0711T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission. |
| 0712T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability. |
| 0713T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report. |
| S8092 | Electron beam computed tomography (also known as ultrafast CT, cine CT). |
| 75571 | Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium. |
| 75572 | Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed). |
| 75573 | Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function, and evaluation of vascular structures, if performed). |
| 75574 | Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed). |
| 0710T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report. |
| 0711T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission. |
| 0712T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability. |
| 0713T | Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report. |
| S8092 | Electron beam computed tomography (also known as ultrafast CT, cine CT). |
Provider Actions and Billing Guidance
Coverage determination
Verify member benefits and applicable state/federal mandates before determining coverage. The policy states that computed tomography (CT) to detect coronary artery calcification (CAC) is considered experimental/investigational and may be a basis for denial; rely on the member's contract at time of service for final coverage determinations.
- Contact Blue Cross and Blue Shield of Kansas Customer Service to verify benefits prior to ordering.
- State and federal mandates and member contract language take precedence over this policy.
Prior authorization for CT/CAC pathways
No explicit prior authorization requirement or formal prior authorization pathway for CAC is specified in this excerpt. When CT-based diagnostic pathways are used (eg, contrast-enhanced cardiac CT/CCTA), follow any prior authorization rules that apply to those services per the member's plan.
- Prior authorization not specified in this policy excerpt — check the member contract and payer prior auth resources.
- If using a CT-based diagnostic pathway that includes CAC as part of tiered testing (eg, calcium scan followed by CCTA), obtain any required prior authorization for the CT/CCTA service per plan rules.
Procedure codes and medical necessity linkage
Procedure and diagnosis codes listed in the Coding section are informational and are considered medically necessary ONLY if the procedure is performed according to the Policy section. Inclusion of a code here does not guarantee coverage or reimbursement.
- Codes are for billing reference only; verify coverage with the member's contract at time of service.
- Medically necessary status is conditional on meeting the Policy criteria described in this document.
Code listing for cardiac CT services
Providers must submit applicable procedure codes when billing for cardiac CT services. The Coding section lists CPT/HCPCS codes relevant to CAC and cardiac CT; include the appropriate code(s) that reflect the service provided.
Policy coverage stance
Computed tomography (CT) to detect coronary artery calcification is considered experimental / investigational per this policy. Use of CAC scoring may be a basis for denial; always refer to the member's contract to determine coverage for an individual member.
- Policy stance: CT to detect CAC = experimental / investigational.
- Refer to member contract benefits at time of service to determine coverage.
Step therapy not specified
This policy excerpt does not specify step therapy or sequencing restrictions beyond describing tiered testing approaches in trial descriptions. There is no formal step-therapy mandate in this text; limit testing to clinical scenarios supported by the policy and member benefits.
- Step therapy not specified — no enforced sequencing defined in this excerpt.
- Clinical trial descriptions suggest limiting CAC scoring to intermediate-risk subjects in some contexts; apply clinical judgment and payer rules.
Expected testing sequence
Trials and observational studies describe an expected testing sequence in some protocols (eg, CAC scan first, followed by selective CCTA if Agatston score between specified thresholds). Consider these tiered approaches when clinically appropriate and when permitted by plan rules.
- Example from Lubbers et al: CAC scan first; if Agatston score 1–400 then proceed to CCTA; CAC=0 often used to rule out CAD in protocols.
- Clinical use should follow policy criteria and member coverage determinations.
Evidence threshold implication
Evidence threshold considerations in the policy include study selection criteria requiring adequate sample sizes and methodological rigor to inform clinical validity. The policy notes that some studies required a minimum of 1000 patients for inclusion in evaluation of clinical validity.
- Study selection criteria: reported marketed technology version, suitable reference standard, described clinical characteristics and selection criteria, and minimum sample size (≥1000) for evaluation of clinical validity.
Bundling of quantitative assessment
When a quantitative coronary calcium assessment is performed during the same encounter as contrast-enhanced cardiac CT (75572, 75573) or coronary CT angiography (75574), the quantitative assessment is included in the service and should not be billed separately.
- If quantitative CAC assessment is performed during the same visit as contrast-enhanced cardiac CT/CCTA, follow bundling rules — it is included in codes 75572–75574.
- Primary fast CT methods include EBCT and MDCT.
Documentation to support use
Document the clinical indication, primary presenting problem (eg, symptomatic evaluation details, pretest risk), and rationale for ordering CAC or cardiac CT. Maintain records that support medical necessity and adherence to policy criteria.
- Include documentation of symptoms (if present), risk stratification, and how test results will affect management.
- For asymptomatic screening requests, note that policy emphasizes use in specific populations and that CAC scoring is considered investigational by this policy.
Required clinical documentation
Required clinical documentation should include a symptomatic evaluation, pretest probability/risk assessment, and indication for testing. Record relevant findings that justify the selected imaging strategy and support medical necessity under the policy.
- Document symptom status (asymptomatic vs symptomatic), clinical history, and risk factors.
- Specify the intended diagnostic pathway (eg, CAC first, then selective CCTA) and how results will influence care.
- Keep contemporaneous notes to support claims if audited.
Coverage verification required
Coverage verification is required — the code list is informational only and does not guarantee coverage. Always refer to the member's contract and verify benefits at the time of service.
- Coding list may not be comprehensive; use the member contract for coverage determinations.
- Contact BCBSKS Customer Service for benefit verification.
Coding inclusion note
Include quantitative calcium assessment codes in the service record when performed during a contrast-enhanced cardiac CT or coronary CTA encounter; the policy states this assessment is considered part of those services and should follow coding inclusion rules.
- Coding inclusion note: quantitative coronary calcium assessment is included in 75572–75574 when performed in the same encounter.
- Primary methods: EBCT and MDCT.
Background and Rationale
Coronary artery calcium (CAC) is quantified on noncontrast cardiac CT (eg, electron‑beam CT, spiral or multidetector CT) as a measure of coronary atherosclerotic burden, commonly expressed as an Agatston score. CAC scoring is associated with the presence and extent of coronary artery disease and has been studied both for long‑term risk prediction in asymptomatic populations and as an adjunct to diagnostic evaluation in symptomatic patients. Although a CAC score of 0 is frequently associated with low event rates and can reduce the likelihood of an atherosclerotic etiology, it does not itself establish ischemia or definitively exclude obstructive disease in all symptomatic patients.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.